The ExoDx Prostate(IntelliScore) test analyzes urine exosomes to provide a risk assessment for high-grade prostate cancer. This genomic test helps clinicians determine whether a patient presenting for an initial prostate biopsy is at high risk for aggressive disease. A negative test result may allow some patients to safely avoid an initial biopsy. A positive test result can provide additional information to support a biopsy decision and guide further management.
This non-invasive approach offers a significant advancement in prostate cancer diagnostics. It helps reduce unnecessary biopsies, minimizing potential complications and patient anxiety associated with the procedure. By identifying those at higher risk, it allows for more focused and efficient use of resources, improving the overall quality of patient care and potentially leading to earlier diagnosis of clinically significant disease. The development of this test reflects a growing trend towards personalized medicine, where diagnostic tools are tailored to individual risk profiles.